What is the official ID of this bill?

The official print number for this legislation is S 898.

When did the legislative process begin?

The process officially started on 2021-03-23.

Where can I read the full text of this legislation?

The full official text is available at: https://www.congress.gov/117/bills/s898/BILLS-117s898is.htm

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-29.

Who is the primary sponsor?

The primary sponsor is Sen. Baldwin, Tammy [D-WI].

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Analysis and Potential Impact of S 898

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

Drug Price Transparency: Manufacturers Must Justify Increases

Q: What are the main provisions?

Key points include: Drug manufacturers must report price increases of 10% over 12 months or 25% over 36 months. Reports must include detailed information on manufacturing costs, research, marketing, and company profits. Information on drug price increases will be publicly available, increasing transparency. Companies failing to report will face high penalties, used to improve drug price information.

This new law requires drug manufacturers to report and justify significant price increases. The goal is to increase transparency in drug costs, which may help citizens understand why prices are rising and potentially impact their access to and cost of treatment, especially for those in Medicare and Medicaid programs.

Key points

Drug manufacturers must report price increases of 10% over 12 months or 25% over 36 months.

Reports must include detailed information on manufacturing costs, research, marketing, and company profits.

Information on drug price increases will be publicly available, increasing transparency.

Companies failing to report will face high penalties, used to improve drug price information.

article Official text account_balance Process page notifications_active Track this Bill

gavel

Status:

Expired

Record your position for audit.

Why does your vote on bills matter?

It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.

Additional Information

Fair Accountability and Innovative Research Drug Pricing Act of 2021

Print number: S 898

Sponsor: Sen. Baldwin, Tammy [D-WI]

Process start date: 2021-03-23

System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.

Summarized by: gemini-2.5-flash-preview-05-20

Source data: api.congress.gov

AI work logs for this document launch

Drug Price Transparency: Manufacturers Must Justify Increases

Key Questions about Drug Price Transparency: Manufacturers Must Justify Increases